Mergers & Acquisitions - Anti-virals


Current filters:


Popular Filters

CSL buys Novartis’ influenza vaccines business for $275 million

CSL buys Novartis’ influenza vaccines business for $275 million


Swiss pharma major Novartis has agreed to divest its influenza vaccines business to Australia’s CSL…

Anti-viralsbioCSLCSL LimitedFinancialMergers & AcquisitionsNovartisPharmaceuticalVaccines

Johnson & Johnson to acquire Alios BioPharma

Johnson & Johnson to acquire Alios BioPharma


US health care giant Johnson & Johnson has signed a definitive agreement to acquire Alios BioPharma,…

AL-8176Alios BioPharmaAnti-viralsJohnson & JohnsonMergers & AcquisitionsPharmaceuticalUSA

Decision Resources Group analyst’s view on Merck’s decision to acquire Idenix

Decision Resources Group analyst’s view on Merck’s decision to acquire Idenix


Given the huge potential, and interest in, the hepatitis treatment market, and US pharma giant Merck…

Anti-viralsIdenix PharmaceuticalsMerck & CoMergers & AcquisitionsPharmaceutical

Ventrus Biosciences boosted on merger plan with Assembly Pharma


USA-based Ventrus Biosciences saw its shares leap 9.4% to $1.16 in pre-market trading, as it announced…

Anti-viralsAssembly BiosciencesAssembly PharmaceuticalsBiotechnologyMergers & AcquisitionsVentrus Biosciences

Biozone Pharma plans reverse merger with Cocrystal Discovery


USA-based Biozone Pharmaceuticals shares dropped nearly 5.5% when it revealed last week it had agreed…

Anti-viralsBiotechnologyBiozone PharmaceuticalsCocrystal DiscoveryMergers & Acquisitions

Vivaldi Biosciences acquires clinical stage influenza vaccine assets


Privately-held US biotech firm Vivaldi Biosciences has acquired from Baxter Healthcare R&D assets, including…

Anti-viralsBaxter HealthcareBaxter InternationalBiotechnologyMergers & AcquisitionsVaccinesVivaldi Biosciences

Revised terms for ViiV Healthcare and Shionogi HIV partnership


UK pharma giant GlaxoSmithKline (LSE: GSK) says that Healthcare, its HIV/AIDS joint venture with Pfizer,…

Anti-viralsdolutegravirGlaxoSmithKlineMergers & AcquisitionsPfizerPharmaceuticalShionogiViiV Healthcare

BioCryst and Presidio to merge, creating new competitor in HCV arena


USA drugmaker BioCryst Pharmaceuticals (Nasdaq: BCRX) has signed a definitive accord to acquire privately…

Anti-viralsBioCryst PharmaceuticalsMergers & AcquisitionsPharmaceuticalPresidio Pharmaceuticals

Australia's Benitec to acquire US RNAi firm Tacere


Australia-based Benitec Biopharma (ASX: BLT) said last Friday that it has executed an agreement to acquire…

Anti-viralsBenitec BiopharmaBiotechnologyMergers & AcquisitionsPharmaceuticalTacere Therapeutics

Achillion Pharma moves up as a contender in the HCV market, GlobalData believes


On September 27, Achillion Pharmaceuticals (Nasdaq: ACHN) released news of positive results surrounding…

ACH-3102Achillion PharmaceuticalsAnti-viralsBiotechnologyMergers & AcquisitionsPharmaceuticalResearch

Synergy Pharma gains rights to shingles drug from Bristol-Myers


US biopharma firm Synergy Pharmaceuticals (Nasdaq: SGYP) has signed an asset purchase agreement with…

Anti-viralsBiotechnologyBristol-Myers SquibbFV-100Mergers & AcquisitionsSynergy Pharmaceuticals

Merck & Co out to lead in hepatitis C


US drugs giant Merck & Co (NYSE: MRK) aims to become a leader in the hepatitis C space, the company’s…

Anti-viralsMerck & CoMergers & AcquisitionsPharmaceuticalResearch

RusNano to start production of vaccines and organogels


Russia’s RusNano (Russian Corporation of Nanotechnologies) has signed an agreement with Russian…

Anti-viralsBiotechnologyCardio-vascularEpidbiomedEuropeFinancialMarkets & MarketingMergers & AcquisitionsNanolekOncologyRusNanoVaccines

Bristol-Myers to buy hep C drug developer for $2.5 billion


Looking to bolster its drug pipeline in the face of US patent expiry of one of its best selling drugs,…

Anti-viralsBristol-Myers SquibbInhibitexMergers & AcquisitionsPharmaceutical

Back to top